Welcome to our dedicated page for Avicanna news (Ticker: AVCNF), a resource for investors and traders seeking the latest updates and insights on Avicanna stock.
Avicanna Inc. (AVCNF) is a commercial-stage international biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived, cannabinoid-based products. The Avicanna news feed on Stock Titan highlights company announcements across its medical cannabis, pharmaceutical, and active pharmaceutical ingredient activities.
Investors and observers can follow updates on Avicanna’s RHO Phyto™ medical cannabis formulary, including clinical and real-world evidence results related to topical creams, transdermal gels, and other cannabinoid-based formulations. News items also cover the MyMedi.ca medical cannabis care platform, which the company describes as a patient-focused service with pharmacist-led support and collaborations with public and private payers.
Avicanna regularly reports milestones in its pharmaceutical pipeline, such as the indication-specific drug registration of Trunerox™ in Colombia for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome, as well as patents granted for topical and oral cannabinoid drug delivery technologies. Additional coverage includes export activities and certifications at its majority-owned subsidiary Santa Marta Golden Hemp SAS, which supplies CBD, THC, and CBG under the Aureus Santa Marta™ brand.
By monitoring Avicanna news, readers can see disclosures on financial performance, clinical collaborations with academic and clinical institutions, regulatory approvals, and international partnerships. This page brings together these company-issued updates in one place, making it easier to review Avicanna’s ongoing work in cannabinoid-based medicine and medicinal and botanical manufacturing.
Avicanna Inc. announced the results of a study conducted at The Hospital for Sick Children on the use of their RHO Phyto™ branded Ultra CBD Topical Cream in patients with Epidermolysis Bullosa. The study evaluated wound healing, pain, and itch, with 55% of patients showing improvements in wound healing and 45% displaying wound stability after one month of daily application. The study results will be presented at Avicanna's symposium on May 13th, highlighting the positive outcomes of the CBD cream in treating EB.
Summary not available.
Summary not available.
Summary not available.
Avicanna has been selected by Shoppers Drug Mart to transition its Medical Cannabis by Shoppers business. This partnership aims to ensure continuity of care for patients as Avicanna introduces MyMedi.ca, a new medical cannabis care platform. MyMedi.ca will offer pharmacist-led patient support programs and a diverse product portfolio. Since its launch in January 2019, Medical Cannabis by Shoppers has supported tens of thousands of patients. The transition is expected to take three months and will enhance access to medical cannabis in Canada, advancing Avicanna’s goal of becoming a leading independent medical cannabis platform.
Avicanna Inc. is launching a real-world evidence study in Montreal to evaluate the efficacy of its RHO Phyto CBG Transdermal Gel for patients with musculoskeletal pain and inflammation. The study will enroll 100 patients and assess the product's effects over a 3-month period, including various types of pain like arthritis and post-surgical pain. Conducted with Santé Cannabis, the research aims to provide insights into localized pain relief using cannabinoid-based topical solutions.
Avicanna has announced the commercialization of its patent-pending, water-soluble technology, Influid, with a THC beverage infuser under the Viola brand in Canada. This innovative formulation uses nanotechnology to improve cannabinoid absorption, addressing issues found in existing products. The product, containing 500 mg of THC per bottle, will initially be available in Ontario through the Ontario Cannabis Store, with plans for expansion into other provinces and medical channels by late Q4 2022. Avicanna also aims to license the Influid technology internationally.
Avicanna Inc. announced an extension agreement for its senior secured term loan, originally reported on August 19, 2021. The maturity date has been pushed back by five months from October 19, 2022, to March 19, 2023. Under this agreement, the company will continue making interest payments and will start repaying the principal monthly from November 2022 until February 2023. The loan carries an interest rate of 5% per annum, calculated monthly. Avicanna focuses on evidence-based cannabinoid products and has a pipeline of pharmaceutical candidates in various stages of development.
Avicanna Inc. has formalized a provisional patent application for its Formulation Candidate aimed at reducing seizures and Sudden Unexpected Death in Epilepsy (SUDEP). This follows successful in-vivo studies conducted with the University of Toronto, indicating significant anti-seizure effects compared to existing treatments. The patent was filed with WIPO, claiming priority from a US application made in September 2022. The company plans to advance this formulation through pre-clinical studies towards future clinical trials.
Avicanna has launched the "Avicenna Academy," a no-cost medical cannabis education portal for healthcare professionals (HCPs). This initiative aims to bridge knowledge gaps about cannabinoid-based products, supporting HCPs with educational resources and practical information. The platform includes modules on various topics, such as the endocannabinoid system and dosing guidelines. Avicanna's efforts focus on expanding access and enhancing patient outcomes in the medical cannabis sector. The portal is part of Avicanna's broader strategy to collaborate with experts and improve training in the medical community.